5 Grok Skills for Clinical Research Document Support
Updated: Nov 12
Clinical research produces a demanding collection of documents: protocols, ethics applications, guideline comparisons, deviation records, and regulatory submissions. An AI assistant can help a team organize these materials, notice inconsistencies, and prepare questions for qualified reviewers.
It cannot approve a trial, determine patient care, certify regulatory compliance, or replace an institutional review board. The useful role is document support with traceable sources and clear review responsibilities.

These five Grok clinical research skills are reusable instruction workflows. Save their instructions in your approved workspace and reuse them with appropriate source material. They are not claims that Grok has a native clinical Skills interface, validated trial software, or direct access to regulatory submission portals.
Establish a safe working boundary
Use public guidance, synthetic examples, or institutionally authorized, appropriately de-identified material. Do not put identifiable patient information into these workflows. Removing names alone may leave identifying dates, rare conditions, locations, or combinations of facts. Have the institution determine what can be used and in which approved environment.
For each task, record the jurisdiction, document version, source date, responsible reviewer, and intended output. Separate regulations from guidance, institutional policy, and a writer's suggested wording. These sources carry different authority and may apply differently across countries and study types.
A reusable starting prompt is:
“Help prepare [document] for professional review. Use only the supplied approved materials and current primary sources for [jurisdiction]. First identify missing information and conflicting versions. For every proposed requirement, give its source and applicability question. Do not invent clinical facts, permissions, signatures, safety assessments, or regulatory conclusions. Return a draft, an evidence map, and unresolved issues assigned to the appropriate reviewer.”
1. Clinical trial protocol checklist
Inputs: The current protocol, study synopsis, schedule of activities, approved template, and applicable guidance. Action: Check whether objectives, eligibility criteria, endpoints, procedures, safety arrangements, data handling, and responsibilities are consistently described. Output: A gap checklist identifying the document section, missing or conflicting information, potential consequence, and review owner. Validation: The investigator, sponsor, statistician, and relevant specialists review the findings through established procedures.
Consider a fictional protocol with a week-eight primary endpoint in the objectives but a week-ten assessment in the visit schedule. Grok should quote the two locations and request a decision. It should not choose a visit window or quietly rewrite the endpoint.
A good checklist also asks whether participant burden and operational complexity are justified by the study's objectives. FDA's E6(R3) Good Clinical Practice guidance emphasizes quality by design, participant protection, proportionate approaches, and reliable results. The workflow can organize a review around these themes; it cannot establish GCP compliance.
Useful copyable instruction: “Compare each endpoint with the schedule, data-collection plan, and analysis plan. Report exact mismatches and questions. Do not make scientific design decisions.”
2. Research ethics and IRB preparation
Inputs: The institution's current application form, protocol, recruitment materials, consent draft, data-flow description, and relevant review policies. Action: Map the planned procedures to the questions reviewers need answered. Output: A draft response set, a consent-language consistency check, and a list of missing safeguards or explanations. Validation: The principal investigator and ethics specialists confirm accuracy before submission to the responsible board or committee.
For example, recruitment text might describe an anonymous survey while the protocol collects identifiable follow-up information. The skill should expose that mismatch and ask the team to resolve it. It should not declare the study exempt or decide that consent is unnecessary.
In the United States, HHS's 45 CFR 46 resources provide the regulatory starting point for research within their scope, including provisions concerning IRB review and informed consent. FDA requirements and institutional or local rules may also apply. Applicability needs professional review.
Keep this skill focused on preparation: explain technical language, identify omissions, and connect answers to supporting documents. Approval, exemption determinations, and consent-waiver decisions remain with authorized institutional processes.
3. Clinical guideline comparison
Inputs: Official guideline documents, publication and update dates, target populations, healthcare settings, and the comparison question. Action: Extract recommendations without stripping away their conditions, evidence assessments, or scope. Output: A comparison matrix showing each source's population, intervention context, recommendation wording, stated certainty, exceptions, and date. Validation: A qualified clinician or guideline methodologist checks the interpretation and relevance.
For example, two guidelines may appear to disagree because one concerns screening an asymptomatic population while the other addresses follow-up after an abnormal finding. The workflow should make that population difference prominent. It must not combine the two into a new treatment algorithm.
Require exact source locations and short quotations where needed, respecting copyright limits. If a guideline uses a different grading system, preserve its terminology and explain the difference rather than inventing a common score. Mark unavailable sections as missing.
Useful instruction: “Compare what the documents say for their stated populations. Identify scope differences and unresolved discrepancies. Do not recommend care for an individual or infer a clinical recommendation where neither source provides one.” The deliverable supports professional evidence review, not patient-specific advice.
4. Protocol deviation and CAPA documentation
Inputs: An authorized, non-identifying event summary, the applicable protocol version, relevant procedures, and the organization's reporting rules. Action: Separate the observed event, its known impact, immediate response, proposed root cause, and evidence still needed. Output: A draft deviation record and corrective and preventive action plan, usually called CAPA, with accountable owners and effectiveness checks. Validation: Quality staff, investigators, sponsors, and the IRB or other bodies review matters within their responsibilities.
Imagine that a visit reminder process failed and several assessments happened outside the permitted window. “Retrain staff” may be insufficient if the underlying scheduling system did not display the window. The skill can propose questions about that process and a test of whether the revised reminder catches future scheduling errors.
Do not let the assistant decide reportability, downgrade an event, or invent a universal reporting deadline. OHRP's incident-reporting resources explain reporting and compliance topics within their scope. The applicable rules, sponsor requirements, and institutional procedures need to be checked for the actual event.
A useful CAPA output distinguishes an immediate correction from a preventive process change. It also states what evidence will show whether the change worked. Proposed actions remain proposals until authorized through the organization's process.
5. Regulatory submission module preparation: IND and 510(k)
Inputs: A pathway confirmed by qualified regulatory staff, current official instructions, an approved source-document inventory, and the specific section to prepare. Action: Build an evidence-to-requirement map and draft only from verified material. Output: A module or section outline, document cross-references, missing-evidence questions, and a review checklist. Validation: Regulatory, scientific, clinical, and quality specialists check the submission before any authorized filing.
An Investigational New Drug application, or IND, concerns investigational drug development and clinical investigation. FDA describes information areas including nonclinical studies, manufacturing, and clinical protocols and investigator information. It is not an approval to market a medicine. See the FDA IND overview.
A 510(k) is a distinct medical-device premarket notification pathway centered on demonstrating substantial equivalence to a legally marketed device when that pathway applies. It is not a generic clinical-trial application, and the term for a successful 510(k) determination is clearance. See the FDA 510(k) overview.
For an IND workflow, the skill might map an existing manufacturing summary to required supporting records. For a 510(k) workflow, it might organize an approved device comparison and its test-report references. Never copy one submission structure into the other or invent a predicate, test result, or compliance claim. Device studies may raise separate investigational requirements that regulatory specialists must assess.
Test the process before using it on live documents
Start with a public template or synthetic protocol containing deliberate inconsistencies. Check whether the workflow finds the conflicts, cites the right sections, and leaves unresolved questions visible. Include a test where the correct answer is “the supplied evidence is insufficient.”
Keep an audit trail of source versions, proposed edits, reviewer decisions, and final approved wording. Any electronic system used for regulated records requires its own assessment; a carefully worded prompt does not validate the system.
For Pegasus, the practical opportunity is a focused document-support workflow that improves the clarity of expert review. Begin with a bounded checklist or evidence map, define who owns each decision, and expand only after the team has tested accuracy, confidentiality, and the handling of uncertainty.





Comments